Talking Medicines targets messaging risk in pharma brand strategy

Tern plc

Pharma teams typically begin with a clear brand narrative built on scientific evidence. But as this narrative moves through marketing, compliance and external agencies, the original message can become diluted. When that happens, healthcare professionals may misinterpret or disengage from the brand. The result is weaker positioning, lower impact and reduced return on marketing investment.

Talking Medicines addresses this problem by offering real-time analytics that measure how healthcare professionals actually receive and interpret brand messages. Instead of waiting for post-campaign reports, teams can see early signals of what is working and adjust strategy before value is lost. This is especially relevant during launch phases, where the ability to course-correct quickly can have a material impact on performance.

Its DrugVoice platform captures unstructured HCP dialogue and turns it into structured insight. This data helps brand teams understand whether their messages are understood, aligned with clinical priorities and prompting the right actions. For leadership, it offers a way to verify that brand strategy is being delivered as intended.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern increases convertible loan note investment in Talking Medicines

Tern has received £270,000 of new unsecured convertible loan notes from Talking Medicines, increasing its total convertible loan note holding to approximately £0.79 million while retaining a 23.8% equity stake.

Tern Plc invests $280,000 in Device Authority convertible loan notes

Tern has invested $280,000 in new unsecured convertible loan notes issued by Device Authority, forming part of a wider funding round of up to $1.6 million from existing investors.

Surgical training technology moves closer to the centre of precision medicine

Fundamental XR is targeting a critical adoption gap in advanced healthcare by using immersive simulation to help surgical teams prepare for complex procedures with greater consistency and scale.

GLP-1 therapies move into a wider investor debate

GLP-1 therapies are moving beyond weight loss and diabetes, creating a wider investor discussion around behaviour, risk and market positioning.

Tern raises £222,000 through share placing

Tern has raised £222,000 before expenses through a placing of 37 million new ordinary shares at 0.60 pence per share, with admission to AIM expected on or around 22 May 2026.

FundamentalXR targets surgical readiness for advanced eye therapies

FundamentalXR is targeting surgical readiness for advanced eye therapies with immersive simulation designed to support real-world adoption.

Search